FDA Still Hasn't Published Hemp Guidance Congress Required

The Food and Drug Administration is running well behind on a hemp-related assignment from Congress, and the legislative branch's own research arm is making sure that fact does not go unnoticed. The Congressional Research Service has again pointed out that the agency has yet to publish two things it was legally directed to produce: a list of known cannabinoids and guidance covering the containers used for hemp products. By the count in the latest reporting, the agency is roughly nine months past its deadline.

The timing makes the delay more noticeable. Federal laws governing hemp and its derivatives are scheduled to change, and many in the industry have argued that those changes will be disruptive. When the rules are shifting, businesses and regulators tend to lean heavily on clear federal guidance, and the absence of that guidance leaves a gap that companies must navigate on their own.

A cannabinoid list matters because it helps define what counts as a known compound in the hemp space, which can influence how products are evaluated and marketed. Guidance on containers addresses packaging, an area where consumer safety and labeling concerns often come up. Without either document, manufacturers and retailers are left guessing about what federal officials will expect.

The congressional researchers are not issuing a penalty, and their reports are informational rather than binding. Still, repeated notes about the missed mandate keep pressure on the agency and give lawmakers and stakeholders a documented reference point when they argue that the rollout of new hemp rules has been rushed or poorly prepared.

For hemp farmers, product makers and shoppers, the takeaway is that significant changes are approaching while some of the promised federal groundwork still has not appeared. Whether the FDA publishes its overdue materials before the new framework takes hold remains an open question.